Response of Central Giant Cell Granuloma of the Jaw to Imatinib

J Pediatr Hematol Oncol. 2023 Jul 1;45(5):278-280. doi: 10.1097/MPH.0000000000002608. Epub 2022 Dec 19.

Abstract

Central giant cell granuloma of the jaw (CGCJ) can be locally aggressive and result in facial and dental deformity. A child with CGCJ was treated surgically and with denosumab with a response but life-threatening toxicity. Imatinib, a tyrosine kinase inhibitor, was prescribed based on clinical similarities between CGCJ and cherubism, for which Imatinib has been effective. Within 2 months, a computed tomographic scan showed significant ossification, which increased over the following 8 months. This case suggests that tyrosine kinase inhibitors may be an effective option, and one with limited toxicity, for CGCJ.

MeSH terms

  • Cherubism* / diagnosis
  • Child
  • Diagnosis, Differential
  • Granuloma, Giant Cell* / diagnosis
  • Granuloma, Giant Cell* / drug therapy
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Imatinib Mesylate